Meta-analysis in medical research: Potentials and limitations

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 3, 2008, Pages 320-329

  Zwahlen, Marcel ^a   Renehan, Andrew ^b   Egger, Matthias ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bias; Heterogeneity; Meta analysis; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; MAGNESIUM; NITRATE;

ADVERSE DRUG REACTION; CLINICAL TRIAL; CONTROLLED STUDY; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; OBSERVATIONAL STUDY; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UROLOGY;

BIOMEDICAL RESEARCH; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; REVIEW LITERATURE AS TOPIC; UROLOGY;

EID: 42949089402     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.12.001     Document Type: Review

References (102)

1. Pearson K. Report on certain enteric fever inoculation statistics. Br Med J 3 (1904) 1246
2. Davis B. What price safety? Risk analysis measures need for regulation, but it's no science. Wall Street Journal, August 6, 1992, p. 1.
3. Susser M. Judgement and causal inference: Criteria in epidemiologic studies. Am J Epidemiol 105 (1977) 1-15
4. In: Egger M., Smith G.D., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 1-487
5. Reynolds J.L., and Whitlock R.M. Effects of a beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset. Br Heart J 34 (1972) 252-259
6. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: Supplementary report. Br Med J 2 (1977) 419-421
7. Baber N.S., Evans D.W., Howitt G., et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. Br Heart J 44 (1980) 96-100
8. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
9. Mitchell J.R. Timolol after myocardial infarction: An answer or a new set of questions?. Br Med J (Clin Res Ed) 282 (1981) 1565-1570
10. Thornley B., and Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 317 (1998) 1181-1184
11. Collins R., Keech A., Peto R., et al. Cholesterol and total mortality: Need for larger trials. BMJ 304 (1992) 1689
12. Teagarden J.R. Meta-analysis: Whither narrative review?. Pharmacotherapy 9 (1989) 274-281
13. Mulrow C.D. The medical review article: State of the science. Ann Intern Med 106 (1987) 485-488
14. Hampton J.R. The use of beta blockers for the reduction of mortality after myocardial infarction. Eur Heart J 2 (1981) 259-268
15. Lau J., Antman E.M., Jimenez-Silva J., et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327 (1992) 248-254
16. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
17. Murphy D.J., Povar G.J., and Pawlson L.G. Setting limits in clinical medicine. Arch Intern Med 154 (1994) 505-512
18. Juni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364 (2004) 2021-2029
19. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333 (1995) 1444-1455
20. Ovarian ablation in early breast cancer: Overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 348 (1996) 1189-1196
21. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 (1998) 1451-1467
22. Chalmers I. The Cochrane collaboration: Preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci 703 (1993) 156-163
23. Clarke M., Stewart L., Pignon J.P., et al. Individual patient data meta-analysis in cancer. Br J Cancer 77 (1998) 2036-2044
24. Clarke M.J., and Stewart L.A. Obtaining individual patient data from randomised controlled trials. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 109-121
25. Pollera C.F. Neoadjuvant chemotherapy: Meta-analysis and interpretation of results in bladder cancer. Suppl Tumori 3 (2004) S59-S61 [in Italian]
26. Nelli F. The SWOG-8710/INT-0080 study: Innovations and controversies concerning neoadjuvant treatment of locally advanced bladder cancer. Suppl Tumori 3 (2004) S57-S58 [in Italian]
27. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109-118
28. Lotan Y., and Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol 167 (2002) 75-79
29. Tan F.E., and Zeegers M.P. An asymptotically unbiased estimator of exposed versus non-exposed odds ratio from reported dose-response data. Stat Methods Med Res 10 (2001) 311-323
30. Neoadjuvant cisplatin for advanced bladder cancer. Advanced Bladder Cancer Overview Collaboration. Cochrane Database Syst Rev (2000) CD001426
31. Scher H.I. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: A meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration. J Urol 154 (1995) 1970
32. Brewer T.F., Wilson M.E., and Nardell E.A. BCG immunization: Review of past experience, current use, and future prospects. Curr Clin Top Infect Dis 15 (1995) 253-270
33. Morris R.D., Audet A.M., Angelillo I.F., et al. Chlorination, chlorination by-products, and cancer: A meta-analysis. Am J Public Health 82 (1992) 955-963
34. De Jager R., Guinan P., Lamm D., et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology 38 (1991) 507-513
35. Lum B.L., and Torti F.M. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83 (1991) 682-694
36. Bouffioux C. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group. Scand J Urol Nephrol Suppl 138 (1991) 167-177
37. Lamm D.L. Comparison of BCG with other intravesical agents. Urology 37 (1991) 30-32
38. Raghavan D., Pearson B., Tynan A., et al. Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: A decade of experience. Semin Urol 8 (1990) 285-290
39. Herr H.W., Jakse G., and Sheinfeld J. The T1 bladder tumor. Semin Urol 8 (1990) 254-261
40. Geller N.L., Scher H.I., Parmar M.K., et al. Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?. Semin Oncol 17 (1990) 628-634
41. Stoter G., Goey S.H., Eggermont A.M., et al. Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek. Biotherapy 2 (1990) 261-265
42. Savitz D.A., and Baron A.E. Estimating and correcting for confounder misclassification. Am J Epidemiol 129 (1989) 1062-1071
43. Scher H., and Herr H. Is chemotherapy a new form of radical treatment in infiltrating tumor localized to the bladder?. Prog Clin Biol Res 303 (1989) 563-582
44. Guinan P., Richardson C., Hanna M., et al. BCG in the management of superficial bladder cancer. Prog Clin Biol Res 303 (1989) 447-453
45. Eysenck H.J. An exercise in mega-silliness. Am Psychol 33 (1978) 517
46. Oakes M. Statistical inference: A commentary for the social and behavioural sciences (1986), John Wiley & Sons, Chichester
47. Boden W.E. Meta-analysis in clinical trials reporting: Has a tool become a weapon?. Am J Cardiol 69 (1992) 681-686
48. Bailar III J.C. The promise and problems of meta-analysis. N Engl J Med 337 (1997) 559-561
49. Yusuf S., Collins R., MacMahon S., et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials. Lancet 1 (1988) 1088-1092
50. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 343 (1994) 1115-1122
51. Teo K.K., and Yusuf S. Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs 46 (1993) 347-359
52. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345 (1995) 669-685
53. Stuck A.E., Siu A.L., Wieland G.D., et al. Comprehensive geriatric assessment: A meta-analysis of controlled trials. Lancet 342 (1993) 1032-1036
54. Reuben D.B., Borok G.M., Wolde-Tsadik G., et al. A randomized trial of comprehensive geriatric assessment in the care of hospitalized patients. N Engl J Med 332 (1995) 1345-1350
55. Imperiale T.F., and Petrulis A.S. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 266 (1991) 260-264
56. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343 (1994) 619-629
57. Felson D.T., Anderson J.J., and Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33 (1990) 1449-1461
58. Gotzsche P.C., Podenphant J., Olesen M., et al. Meta-analysis of second-line antirheumatic drugs: Sample size bias and uncertain benefit. J Clin Epidemiol 45 (1992) 587-594
59. Gotzsche P.C., and Olsen O. Is screening for breast cancer with mammography justifiable?. Lancet 355 (2000) 129-134
60. de Koning H.J. Assessment of nationwide cancer-screening programmes. Lancet 355 (2000) 80-81
61. Olsen O., and Gotzsche P.C. Cochrane review on screening for breast cancer with mammography. Lancet 358 (2001) 1340-1342
62. Altman D.G. Practical statistics for medical research (1991), Chapman and Hall, London
63. Juni P., Altman D.G., and Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 323 (2001) 42-46
64. Schulz K.F., Chalmers I., Hayes R.J., et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995) 408-412
65. Smith R. What is publication?. BMJ 318 (1999) 142
66. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 263 (1990) 1385-1389
67. Scherer R.W., Dickersin K., and Langenberg P. Full publication of results initially presented in abstracts. A meta-analysis. JAMA 272 (1994) 158-162
68. Easterbrook P.J., Berlin J.A., Gopalan R., et al. Publication bias in clinical research. Lancet 337 (1991) 867-872
69. Stern J.M., and Simes R.J. Publication bias: Evidence of delayed publication in a cohort study of clinical research projects. BMJ 315 (1997) 640-645
70. Dickersin K., Min Y.I., and Meinert C.L. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267 (1992) 374-378
71. Dickersin K. How important is publication bias?. A synthesis of available data. AIDS Educ Prev 9 (1997) 15-21
72. Dickersin K., and Min Y.I. NIH clinical trials and publication bias. Online J Curr Clin Trials (1993) Doc No. 50
73. Egger M., Dickersin K., and Davey Smith G. Problems and limitations in conducting systematic reviews. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 43-68
74. Simes R.J. Confronting publication bias: A cohort design for meta-analysis. Stat Med 6 (1987) 11-29
75. Simes R.J. Publication bias: The case for an international registry of clinical trials. J Clin Oncol 4 (1986) 1529-1541
76. Sackett D.L. Bias in analytic research. J Chronic Dis 32 (1979) 51-63
77. In: Rothman K.J., and Greenland S. (Eds). Modern epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia (PA) 1-737
78. Egger M., Davey Smith G., and Schneider M. Systematic reviews of observational studies. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 211-227
79. Altman D.G. Systematic reviews of evaluations of prognostic variables. BMJ 323 (2001) 224-228
80. Deeks J.J. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323 (2001) 157-162
81. Smith-Warner S.A., Spiegelman D., Yaun S.S., et al. Alcohol and breast cancer in women: A pooled analysis of cohort studies. JAMA 279 (1998) 535-540
82. Hamajima N., Hirose K., Tajima K., et al. Alcohol, tobacco and breast cancer-Collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87 (2002) 1234-1245
83. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (2002) 187-195
84. Egger M., May M., Chene G., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
85. Chene G., Sterne J.A., May M., et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 362 (2003) 679-686
86. Sackett D.L., Deeks J.J., and Altman D. Down with odds ratios!. Evidence-Based Medicine 1 (1996) 164-166
87. Deeks J. When can odds ratios mislead?. Odds ratios should be used only in case-control studies and logistic regression analyses. BMJ 317 (1998) 1155-1156
88. Laupacis A., Sackett D.L., and Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988) 1728-1733
89. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
90. Deeks J.J., Altman D., and Bradburn M.J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 285-312
91. Sweeting M.J., Sutton A.J., and Lambert P.C. What to add to nothing?. Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004) 1351-1375
92. Greenland S., and Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135 (1992) 1301-1309
93. Chene G., and Thompson S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144 (1996) 610-621
94. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
95. Sterne J., Egger M., and Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M., Smith G.D., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 189-208
96. Sterne J., Egger M., and Sutton A.J. Meta-analysis software. In: Egger M., Smith G.D., and Altman D.G. (Eds). Systematic reviews in health care: Meta-analysis in context. 2nd ed. (2001), BMJ, London (UK) 336-346
97. Prevost T.C., Abrams K.R., and Jones D.R. Hierarchical models in generalized synthesis of evidence: An example based on studies of breast cancer screening. Stat Med 19 (2000) 3359-3376
98. Spiegelhalter D.J., Myles J.P., Jones D.R., et al. Bayesian methods in health technology assessment: A review. Health Technol Assess 4 (2000) 1-130
99. Higgins J.P., and Spiegelhalter D.J. Being sceptical about meta-analyses: A Bayesian perspective on magnesium trials in myocardial infarction. Int J Epidemiol 31 (2002) 96-104
100. Spiegelhalter D.J. Incorporating Bayesian ideas into health care evaluation. Stat Sci 19 (2004) 156-174
101. Spiegelhalter D.J., Abrams K.R., and Myles J.P. Bayesian approaches to clinical trials and health-care evaluation (2004), John Wiley & Sons, London (UK) 1-391
102. The Cochrane Collaboration. http://www.cochrane.org Accessed January 1, 2007